ACP
SEEL

Acuta Capital Partners’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Acuta Capital Partners’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-77
Closed -$248K – 50
2022
Q1 		$248K Sell
77
-574
-88% -$2.47M 0.12% 39
2021
Q4 		$4.08M Sell
651
-94
-13% -$722K 1.71% 20
2021
Q3 		$6.89M Hold
745
– – 2.43% 12
2021
Q2 		$7.55M Buy
745
+297
+66% +$4.88M 3.02% 10
2021
Q1 		$8.58M Buy
+448
New +$5.23M 3.09% 10

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acuta Capital Partners's SEEL Position: Q2 2022 in Review

Acuta Capital Partners sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2022, closing a stake of 77 shares — an estimated $248K sold.

Acuta Capital Partners first reported a position in SEEL in Q1 2021 and held it in 5 quarters. The position peaked at $8.58M in Q1 2021. 65 funds tracked by Wall St. Rank hold SEEL as of Q2 2022.

  • Acuta Capital Partners reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 77 Seelos Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $248K.
  • Acuta Capital Partners first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Acuta Capital Partners's Seelos Therapeutics, Inc. Common Stock position peaked at $8.58M in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Acuta Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.